Rajabi MR, et al. Long-term systemic effects of metabolic bariatric surgery: a multidisciplinary perspective. Heliyon. 2024;10(14): e34339.

PubMed  PubMed Central  Google Scholar 

Cummings DE, Cohen RV. Bariatric/metabolic surgery to treat type 2 diabetes in patients with a BMI <35 kg/m2. Diabetes Care. 2016;39(6):924–33.

PubMed  PubMed Central  Google Scholar 

Roth AE, Thornley CJ, Blackstone RP. Outcomes in bariatric and metabolic surgery: an updated 5-year review. Curr Obes Rep. 2020;9(3):380–9.

CAS  PubMed  Google Scholar 

Abi Mosleh K, et al. Assessment of predictors of acute kidney injury and progression to chronic kidney disease following bariatric surgery. Surg Obes Relat Dis. 2025;21(4):382–8.

PubMed  Google Scholar 

Weingarten TN, et al. Acute kidney injury following bariatric surgery. Obes Surg. 2013;23(1):64–70.

PubMed  Google Scholar 

Abdullah HR, et al. Predictors of perioperative acute kidney injury in obese patients undergoing laparoscopic bariatric surgery: a single-centre retrospective cohort study. Obes Surg. 2016;26(7):1493–9.

PubMed  Google Scholar 

Gameiro J, Marques F, Lopes JA. Long-term consequences of acute kidney injury: a narrative review. Clin Kidney J. 2021;14(3):789–804.

CAS  PubMed  Google Scholar 

Chertow GM, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. Journal of the American Society of Nephrology. 2005;16(11):3365–70.

PubMed  Google Scholar 

Scheen AJ. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):556–77.

PubMed  Google Scholar 

Arnott C, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(3): e014908.

PubMed  PubMed Central  Google Scholar 

Heerspink HJL, et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26–39.

CAS  PubMed  Google Scholar 

Ravindran S, Munusamy S. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. J Cell Physiol. 2022;237(2):1182–205.

CAS  PubMed  Google Scholar 

Kim NH, Kim NH. Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diabetes Metab J. 2022;46(4):543–51.

PubMed  PubMed Central  Google Scholar 

Takashima H, et al. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial. Diab Vasc Dis Res. 2018;15(5):469–72.

CAS  PubMed  Google Scholar 

Maxson R, et al. SGLT2 inhibitors to slow chronic kidney disease progression: a review. Clin Ther. 2024;46(1):e23–8.

CAS  PubMed  Google Scholar 

Herrington WG, et al. Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med. 2025;392(8):777–87.

CAS  PubMed  Google Scholar 

Miyamoto S, et al. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney Int. 2024;106(5):972–84.

CAS  PubMed  Google Scholar 

McEwan P, et al. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrol Dial Transplant. 2024;39(12):2040–7.

CAS  PubMed  PubMed Central  Google Scholar 

Goldenberg RM, et al. SGLT2 inhibitor–associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38(12):2654–2664.e1.

CAS  PubMed  Google Scholar 

Shafiq A, et al. The dual role of empagliflozin: cardio renal protection in T2DM patients. Annals of Medicine and Surgery. 2022;81:81.

Google Scholar 

Ho CN, et al. Impact of general vs. regional anaesthesia on one‐year clinical outcomes and healthcare utilisation after lower limb arthroplasty: a retrospective study. Anaesthesia. 2025;80(5): 488-498.

Ho C-N, et al. Impact of preoperative QTc interval prolongation on short-term postoperative outcomes: a retrospective study. J Clin Anesth. 2024;98: 111574.

PubMed  Google Scholar 

Snel LIP, et al. The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: an open-label randomized pilot study. J Clin Anesth. 2025;103: 111811.

CAS  PubMed  Google Scholar 

Wang R, et al. The impact of diabetes mellitus on acute kidney injury after coronary artery bypass grafting. J Cardiothorac Surg. 2020;15(1):289.

PubMed  PubMed Central  Google Scholar 

Wang Y-J, et al. Diabetes mellitus is a risk factor of acute kidney injury in liver transplantation patients. Hepatobiliary Pancreat Dis Int. 2021;20(3):215–21.

CAS  PubMed  Google Scholar 

Kim NY, et al. Effect of diabetes mellitus on acute kidney injury after minimally invasive partial nephrectomy: a case-matched retrospective analysis. J Clin Med. 2019;8(4): 468.

PubMed  PubMed Central  Google Scholar 

Dutta S, et al. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. Journal of Family Medicine and Primary Care. 2022;11(3):927–40.

PubMed  PubMed Central  Google Scholar 

Llorens-Cebrià C, et al. Antioxidant roles of SGLT2 inhibitors in the kidney. Biomolecules. 2022;12(1):143.

PubMed  PubMed Central  Google Scholar 

Yaribeygi H, et al. Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art. Excli J. 2023;22:53–66.

PubMed  PubMed Central  Google Scholar 

Tsai KF, et al. Emergence of SGLT2inhibitors as powerful antioxidants in human diseases. Antioxidants (Basel), 2021;10(8):116. https://doi.org/10.3390/antiox10081166

Sun LY, et al. Association of intraoperative hypotension with acute kidney injury after elective noncardiac surgery. Anesthesiology. 2015;123(3):515–23.

PubMed  Google Scholar